In Situ Crosslinked Hydrogel Depot for Sustained Antibody Release Improves Immune Checkpoint Blockade Cancer Immunotherapy

The therapeutic inhibition of immune checkpoints, including cytotoxic T lymphocyte-associated protein (CTLA)-4 and programmed cell death 1 (PD-1), through the use of function blocking antibodies can confer improved clinical outcomes by invigorating CD8+ T cell-mediated anticancer immunity. However, low rates of patient responses and the high rate of immune-related adverse events remain significant challenges to broadening the benefit of this therapeutic class, termed immune checkpoint blockade (ICB). To overcome these significant limitations, controlled delivery and release strategies offer unique advantages relevant to this therapeutic class, which is typically administered systemically (e.g., intravenously), but more recently, has been shown to be highly efficacious using locoregional routes of administration. As such, in this paper, we describe an in situ crosslinked hydrogel for the sustained release of antibodies blocking CTLA-4 and PD-1 signaling from a locoregional injection proximal to the tumor site. This formulation results in efficient and durable anticancer effects with a reduced systemic toxicity compared to the bolus delivery of free antibody using an equivalent injection route. This formulation and strategy thus represent an approach for achieving the efficient and safe delivery of antibodies for ICB cancer immunotherapy.

[1]  S. Thomas,et al.  Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy , 2020, Science Translational Medicine.

[2]  Zhuang Liu,et al.  In Situ Formed Fibrin Scaffold with Cyclophosphamide to Synergize with Immune Checkpoint Blockade for Inhibition of Cancer Recurrence after Surgery , 2019, Advanced Functional Materials.

[3]  Kyung Soo Park,et al.  Cancer nanomedicine for combination cancer immunotherapy , 2019, Nature Reviews Materials.

[4]  Jihoon Kim,et al.  Augmenting the synergies of chemotherapy and immunotherapy through drug delivery. , 2019, Acta biomaterialia.

[5]  Hao Cheng,et al.  A Dual‐Bioresponsive Drug‐Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade , 2019, Advanced materials.

[6]  Weikang Hu,et al.  Advances in crosslinking strategies of biomedical hydrogels. , 2019, Biomaterials science.

[7]  Y. Lim,et al.  Degradation‐Regulatable Architectured Implantable Macroporous Scaffold for the Spatiotemporal Modulation of Immunosuppressive Microenvironment and Enhanced Combination Cancer Immunotherapy , 2018, Advanced Functional Materials.

[8]  Quanyin Hu,et al.  Delivery Strategies for Immune Checkpoint Blockade , 2018, Advanced healthcare materials.

[9]  Zhen Gu,et al.  Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade , 2018, Advanced materials.

[10]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[11]  Zhuang Liu,et al.  In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy , 2018, Science Translational Medicine.

[12]  Huadan Xue,et al.  Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments. , 2018, Cancer letters.

[13]  V. Engelhard,et al.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity , 2018, The Journal of Immunology.

[14]  Gordon J. Freeman,et al.  T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity , 2017, Nature Communications.

[15]  Huadan Xue,et al.  Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-64Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy. , 2017, Molecular pharmaceutics.

[16]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[17]  Mark R Prausnitz,et al.  Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin. , 2017, Annual review of chemical and biomolecular engineering.

[18]  S. Thomas,et al.  Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy , 2017, Advanced drug delivery reviews.

[19]  Yanan Cui,et al.  Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system , 2017, Drug development and industrial pharmacy.

[20]  David J. Mooney,et al.  Designing hydrogels for controlled drug delivery. , 2016, Nature reviews. Materials.

[21]  Zhen Gu,et al.  Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody , 2016, Advanced materials.

[22]  Quanyin Hu,et al.  Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors. , 2016, ACS nano.

[23]  K. Thurecht,et al.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.

[24]  Zhen Gu,et al.  Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. , 2016, Nano letters.

[25]  Nikhil S. Joshi,et al.  Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. , 2015, Immunity.

[26]  Won Jong Kim,et al.  Enhanced tumor-targeted gene delivery by bioreducible polyethylenimine tethering EGFR divalent ligands. , 2015, Biomaterials science.

[27]  C. Jackisch,et al.  Subcutaneous Administration of Monoclonal Antibodies in Oncology. , 2014, Geburtshilfe und Frauenheilkunde.

[28]  H. Kohrt,et al.  Intratumoral Immunization: A New Paradigm for Cancer Therapy , 2014, Clinical Cancer Research.

[29]  F. Hourcade‐Potelleret,et al.  Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen , 2012, Arzneimittelforschung/Drug Research.

[30]  D. Mager,et al.  Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats , 2012, Pharmaceutical Research.

[31]  Won Jong Kim,et al.  NONOates--polyethylenimine hydrogel for controlled nitric oxide release and cell proliferation modulation. , 2011, Bioconjugate chemistry.

[32]  Chaoliang He,et al.  In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[33]  R. Vile,et al.  Intratumoral immunotherapy: using the tumour against itself , 2005, Immunology.

[34]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.

[35]  Y. Zamzam,et al.  Tumor Infiltrating Lymphocytes and Tertiary Lymphoid Structure as Prognostic and Predictive Factor for Neoadjuvant Chemotherapy in Stage II & III Breast Cancer , 2018 .